Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose psilocybin for alcohol use disorder
2024-517497-17-01Phase 2Completed
- Sponsor
- Capital Region of Denmark
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcohol use disorder (AUD) comparing PEX010 psilocybin with Placebo (2 arms). Primary endpoint: Percentage of heavy drinking days during the last 28 days. Started Sep 2023; status: completed.
02
Drugs
PEX010
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on 2024-517497-17-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517497-17-01.